This questionnaire survey study examined the effectiveness of project management systems for drug development at the United States research and development (R&D) laboratories of six large. multinational pharmaceutical firms. In this sample of 45 teams, project performance is higher in those firms using a dual-leader project management system. Project performance is higher when functional managers have greater influence over go/no go decisions and project leaders have greater influence over clinical decisions. The technical knowledge of the project leader is related to project performance in a complex fashion. Across firms in the sample, team members do not feel that teams have autonomy to carry out their mission, organizations do not have clear criteria for assessing team performance, and individual team member rewards are not linked to their performance as a project team member.
INTRODUCTION
BRINGING NEW DRUGS from discovery through development to market is costly, time consuming, and risky. For firms in the ethical segment of the pharmaceutical industry this is an important task because these firms rely on positive economic profits from the successive rounds of patented prescription drugs they develop and market to fund the next round of discovery and development.
In response to the increasingly competitive environment, managers in this industry seek to make their firms more efficient Reprint address: Frank Basa, MD, 38 Memorial Drive, Room E56-390, Cambridge, MA 02142-1347.
*Support for this study was provided by the Sloan foundation and by the Program on the Pharmaceutical Inductry, MIT and effective at drug development. Their goals are to reduce the cost and time needed to discover a new chemical entity, to generate evidence of its safety and efficacy, and to launch it on the market as a new therapeutic agent. Managers in the pharmaceutical industry are trying to accomplish this partly by experimenting with practices they observe in other industries, hoping to gain the benefits that are attributed to these practices.
Across a portion of firms in the pharmaceutical industry, managers are revamping the systems they employ to coordinate project activities. The two changes most frequently mentioned by senior and upper-middle level R&D managers are: giving project leaders more control over project decisions and budgets, and empowering teams. These prescriptions are partially drawn from recent research in the 621 automobile industry and from the popular business press that espouse the benefits of project organization and team empowerment (1,2).
While strong project organization does lead to more rapid new product development in the automobile industry (l), there are a series of underlying structural aspects of this task in the pharmaceutical industry, as well as in others, that raise questions concerning the limitations of these organizational mechanisms, particularly in R&D-intensive industries where there is significant uncertainty about the outcome of development projects.
This paper summarizes an empirical examination of the current state of project management in the R&D laboratories of six multinational pharmaceutical firms. The results presented below may be useful to managers attempting t o improve the effectiveness and efficiency of drug development in their organizations. These results demonstrate a significant difference in performance between the two primary forms of project leadership that occur in the industry. The results also indicate that the organizational milieu in which development teams generally operate in the industry has shortcomings.
THEORETICAL OVERVIEW
To aid the coordination of activities and integration of information and expertise, pharmaceutical firms have implemented a variety of organizational structures and systems to manage new product development projects. These structures and systems establish the conduits for bringing information from divergent sources to those people and groups responsible for making strategic and operational decisions. They operate along lateral, hierarchical, and temporal lines to coordinate and control activities.
The research this report summarizes is based on the premise that project coordination systems vary in their effectiveness, and that this variance is caused, in signifi-cant part, by the details of the organizational structure and arrangements implemented in each firm, as well as by how these are enacted during the course of each development project.
The structures and systems employed in the pharmaceutical industry are much the same as those used in R&D laboratories in other industries. They range from pure functional organizations structured along departmental lines that have only very weak project coordinators performing primarily a clerical role through to true project organizations where project leaders control budgets and task assignments and have final authority over project decisions. Most larger R&D laboratories, including those in the pharmaceutical industry, employ a matrix arrangement that lies between these two extremes where a project focus and dotted line reporting relationships for the team members are overlayed on a functional backbone (3,4).
There are trade-offs that are made with any organization structure. By organizing along any particular dimension of a task, other dimensions along which organizational attention and coordination is needed may be neglected ( 5 ) . Strong functional organizations link technical people back to their specialties well, but are slow at performing tasks that involve cross-department interdependencies. Project organizations are much faster at coordinating across departments because people are directly responsible to the project head, but project organizations tend to isolate technical personnel from others in their field. Over time technical specialists performing project work lose touch with the advances in their field, eroding the technical knowledge base of the firm. This is especially the case when the underlying technologies are evolving quickly.
Matrix structures have an underlying departmental organization that helps people keep abreast of advances in their technical field. These structures also allow efficient sharing of specialized resources because people can be assigned to multiple projects. Finally, the project side of the matrix provides a formal mechanism for organizing across departments as a way of speeding task completion. These benefits are not without cost. The matrix structure is complex and causes conflict, primarily over personnel assignments and resource allocation.
When used appropriately, matrix structures are able to accomplish tasks involving interdependencies that require crossdepartment coordination more quickly than functional organizations. Matrix project teams are a mechanism for bringing cross-functional expertise and representation to project decision making. These teams allow information regarding interdependencies among subtasks and departments to be shared quickly. The concomitant delegation of decision making authority for some cross-department issues reduces the time required for conducting interdependent development activities because every cross department issue and decision does not need to make its way up the hierarchy for resolution.
The ability of upper-level managers to delegate authority and responsibility for cross-functional tasks to lower levels in the organization reduces the attention these managers need to pay to operational issues while keeping sight of the goal of getting a product to market. This reduces the cognitive load on upper-level managers and pushes decision making authority for many operational issues lower in the organization where personnel closer to the issues who have the information needed for many operational decisions are located.
While delegating relieves senior managers of part of their managerial workload and may bring greater technical expertise and attention to decisions, it also limits the perspective employed in making project decisions. This narrows the decision makers' scope of objectives and, in some cases, excludes an overview of the organization's overall strategy from project-level decision making (Figure 1 ).
Functional managers and project leaders have perspectives driven by where they reside in the organization, the time frames in which they think about the world, the goals they pursue, and the means they view as appropriate to achieve these goals (6). The differences in agendas are often rational and largely due to the reward expectancies and priorities held by project and functional managers (7). Functional managers are responsible for technical aspects ef the task, while project leaders are responsible for getting a product to market.
Project leaders are concerned with the multitude of technical, organizational, regulatory, and business decisions made during the course of their development projects. Project portfolio issues are of less concern, except as they affect their projects, their careers, and the departments from which they are drawn. Functional managers, on the other hand, attend to specific projects when they require services from their departments. Portfolio issues may be more salient to the functional managers, because portfolio decisions can affect departmental workloads, staffing levels, and budgets. These differences generate rational but possibly also dysfunctional behaviors. Functional managers may be more concerned with the workflow in their departments and may not prioritize projects in a manner consistent with an overarching organizational perspective, possibly slowing down high priority projects or keeping projects alive to keep people in their departments working. Conversely, project leaders may overestimate the importance of their project or may not be objective in their assessments of the viability of their compound at go/no go decision points. Senior managers retain authority over some decisions as a way of controlling lower level managers, arbitrating conflicts between project teams and departments when necessary, and providing overall direction to development activities.
There is a tension between bringing ad- equate functional expertise from the departments, a focus on the product from the project, and a perspective that includes the overall organizational strategy from the upper levels of management to decision making on project teams. This problem is not unique to the pharmaceutical industry. Across industries in which firms are developing new products there is a need to align or at least to have constructive conflict between the functional and project sides of organizations.
Past research relating matrix organization to R&D project performance points to the importance of the distribution of influence between project and functional management as a driver of project performance. Katz and Allen (8) found that projects are rated as higher performing by senior managers when project team members perceive functional managers t o have greater control over technical decisions relating to the project, and project managers to have greater influence over pay and promotion decisions and to have more overall power in the organization. These authors reasoned that the functional manager's control over technical decisions ensures a high quality design, while the project manager's control over team member rewards keeps them focused on getting a product to market. Katz and Allen's find-ings are very similar to Marquis and Straight's (9) findings that stronger project control correlates with better schedule performance and fewer cost overruns, while stronger functional control is associated with better technical performance.
Clark and Fujimoto (1) found that faster design cycle times were associated with heavyweight product managers who had significant formal or informal power to make decisions, mobilize resources, and direct the personnel assigned to the project. The heavyweight product managers had direct contact with engineers in departments performing project tasks. In this way they were able to ensure that the essential aspects of the product concept were translated into engineering specifications and were not lost in the morass of issues and compromises encountered in the development of an automobile. The heavyweight product managers did not rely upon functional managers to safeguard the product concept. They also did not wait for the functional managers. They were proactive and, to some degree, intrusive in departmental matters relating to their project.
Larsen and Gobeli (3) classified matrix structures into five categories representing a spectrum of power sharing between the functional and project sides of the organi-zation: pure functional, functional matrix, balanced matrix, project matrix, and pure project. In their study of projects across a range of industries they found the project matrix to be the structure associated with the greatest percentage of successful projects and the balanced matrix to be the second most effective.
While these results differ, they demonstrate that organization structure affects project performance. The inconsistant findings may be due to variance in the uncertainty of tasks being performed by the organizations across the studies. Woodward (10) and others ( 5 , l l ) have shown that the greater the uncertainty inherent in a task, the more difficult to anticipate and plan for possible outcomes beforehand, and the more adaptable an organization needs to be to effectively accomplish the task. Tasks that are routine and involve little uncertainty can be planned for in advance and executed effectively by a more bureaucratic organization. Nonroutine tasks entailing greater uncertainty require a less rigid organization for effective execution.
Pharmaceutical development involves subtasks with significant uncertainty as well as other subtasks entailing little uncertainty. For the subtasks entailing less uncertainty, routine organizational procedures and communication channels can be utilized to accomplish the subtasks efficiently and with a minimum of unplanned activity ( 5 ) . The gathering of preclinical data regarding toxicity, metabolism, pharmacokinetics, and, in some cases, even efficacy is done via well-established protocols. The gathering of data in humans can also involve relatively little uncertainty, although for highly novel drugs or drugs where therapeutic effects are difficult t o assess, significant uncertainty is involved. The organizational systems that perform routine studies and transmit the results can be systematized. Strategic decisions to undertake a particular development project or to pursue a set of projects in a portfolio require adaptive organizational action that cannot be planned for before-hand and routinized because the majority of new chemical entities (NCEs) that enter into early development never make it into humans. It is impossible to predict apriori whether a drug will be safe and adequately efficacious. Likewise, while some tests are readily performed, interpreting the results is problematic. Any organization system that develops new drugs effectively must take into account the variation in uncertainty of the subtasks involved in the overall process.
The very high uncertainty involved in pharmaceutical development is one of two key characteristics that distinguish it from new product development in other industries. In engineering design tasks there are uncertainties, but they are different from those encountered in drug development. For many engineering design efforts the outcome is feasible, although the time and cost required to get there may be difficult to project. By applying enough effort some design will be produced regardless of its elegance or success in the market. in drug development, however, a candidate compound is tested until it passes or fails.
Designing around certain types of obstacles is possible, but if a compound has significant toxicity or if it has no efficacy then there is no option other than to discontinue development. Searching for a similar molecule with greater efficacy or less toxicity may be options, but the fundamental task of developing an NCE (as opposed to a reformulation of a previously approved drug) entails far greater uncertainty than designing an automobile. The second distinguishing characteristic of pharmaceutical development is the large number of doctoral level specialists who are involved in development projects. The technical demands of the task require highly trained personnel whose primary identification may be to their academic specialty rather than to the organization in which they work (12) . This has two effects. First, motivating these researchers to work toward the goal of getting a product to market may be difficult. Second, the highly technical nature of the task makes it difficult for any single manager to understand all the technologies well enough to be competent to make decisions across areas. Clark and Fujimoto's heavyweight product managers probably understand the range of technologies automobile design entails to a level where they are able to comprehend the trade-offs between technical design decisions and the product concept.
METHOD
The study is an interview and crosssectional correlation survey design. Managers in the industry and consultants were interviewed to provide a qualitative description of drug development and to aid in writing the surveys used to gather quantitative data. Questionnaires were administered to a sample of teams, project leaders, and senior managers at six major pharmaceutical firms. Four of these firms are in the top 10 by sales in the industry; the remaining two are in the top 15.
The sample of teams surveyed at each firm was chosen by managers working in those firms. A total of 45 projects are included in this study. The managers responsible for assigning teams were asked to choose a sample that contained variance in phase of development, therapeutic area, and performance. Team members, team leaders, and team coordinators, in the three firms with dual leader systems, and senior managers were surveyed.
The team member, team leaders, and team coordinators received similar surveys. The first portion of the survey focuses on a series of decisions that are made or that might be made during a development project. These decisions range from early ones concerning the choice to take a chemical entity into development through decisions made during the preclinical and clinical phases of drug development. For each of these items team members are asked to assess the relative influence of their project team leader and, if their project has one, their team coordinator, as compared to department managers on a seven-point Likert scale as it pertains to each of these decisions (Table 1) . Team members are also asked that in those cases where senior managers or committees are the true decision makers they indicate whether the project leader and coordinator versus department management has had or expects to have greater influence with the actual decision makers. Factor scales of these items are the primary operationalization of organization structure in the study.
The second section of the questionnaire asks team members to assess their project leaders' managerial skills, influence in the organization, and technical knowledge and understanding. Team members were not asked to assess the project coordinator, if that role existed in their firm. Project coordinators are omitted from this section of the survey; the focus is on the team leader. Only team members answered these questions. Team leaders were not asked to assess themselves.
The final section of the survey queries perceptions of the team and how it operates within the organization in which it is embedded. This portion of the survey was administered to team members, team leaders, and project coordinators.
The survey administered to project leaders and, in those firms that had them, coordinators, is largely the same as the team member questionnaire. Those items that refer to the locus of decision influence and team functioning are identical for team members and leaders/coordinators in each of the firms. The most significant difference between the team member and leader/coordinator surveys is in the second section that focuses on team leader characteristics. That portion of the team member survey is replaced in the leader/ coordinator survey with a number of items querying the history of the project and characteristics of the technology and development organization.
While the questionnaires are largely identical there are minor variations from firm to firm because the surveys were tai- lored to fit the language and organizational systems employed in each of the organizations. Firms differ in the terms used to refer to team leaders. In some organizations the person is called project director, while in others he or she is referred to as project chair or cochair or project leader. Several of the organizations have a dual leadership structure. These firms have a separate person with the title of project manager or coordinator drawn from a staff department. People in this role assist the project leader by tracking the schedule and by keeping tabs on the progress of tasks in each of the departments. The senior manager questionnaire has a completely different focus. It asks upper level managers to assess the performance of each of the development projects and team leaders. It also queries senior managers on how well the technology fits the R&D strategy and capabilities of the organization as well as their expectations for the product in the marketplace.
RESULTS
The results presented below focus on the relationships among the two primary forms of project leadership, phase of the development project, characteristics of the team leader, characteristics of the team milieu inside firms, and project performance. (Project leadership takes two primary forms in the pharmaceutical industry. The first has a single project leader drawn from a project management department or from a technical department. The second form has a dual leadership structure with a project head who is drawn from either a technical department or an administrative department, but who has significant technical experience, and a project coordinator drawn from a project management department. Project leaders in the sample from firms having a dual leader system all hold doctorates and have significant technical experience. In the single leader system, some project heads do not have doctorates and some are business people with no technical training.) Before getting into these analyses, a brief description of the sample and data aggregation methods are presented.
The sample in the study consists of 45 teams from six major pharmaceutical firms. Four of the firms are in the top 10 by sales and the remaining two are in the top 20 firms in the industry. Sixteen percent of the projects were in the preclinical phase at the time of surveying, 23% were in or just finishing Phase 1, 3 1 Yo were in or just finishing Phase 2, 27% were in Phase 3, and 4% had completed Phase 3 testing and were either in the final stages of new drug application (NDA) preparation or were awaiting Food and Drug Administration (FDA) response to the NDA.
Projects are divided into early (Phases 0 and 1) and late (Phases 2 and 3) phase projects for parts of the analysis below. This serves as a crude operationalization of the evolution of the development task from nonhuman trials to clinical trials.
Responses for the decision items, team leader characteristic items, and a subset of the team functioning items were each factor analyzed using listwise deletion, principal components extraction, and varimax rotation. The extracted factors were used as guides in selecting items representative of the inferred underlying constructs (Tables 2, 3,4) . Mean values for each construct were calculated by team member and then aggregated by team. The team means for the decision and project leader scales are listed in Tables 5 and 6 . The team related items are listed individually and not aggregated into scale values (Table  7) . This is done to make the extreme values on the three items assessing the organizational support for teams more salient.
Team performance assessments by senior managers were averaged across those senior managers who indicated they were familiar enough with each project to be 
Locus of Decision Influence and Project Performance
The scale values in Table 5 were used to categorize teams into those with greater departmental management influence versus greater project management influence versus a more balanced system where influence is equal between both sides of the organization. The middle Likert scale category (between 3.5 and 4.5 units) is used as the criterion for defining teams with a balance between project and departmental management influence. Listed in Table 8 are the percentages of teams in each category broken down by single versus dual leadership structure.
These data indicate that regardless of leadership structure functional managers are perceived to have greater influence over personnel, resource allocation, and reward decisions. Conversely, influence over tactical operational decisions, as operationalized by the preclinical and clinical scales, lies toward the project side of the organization. For late stage projects there is a more pronounced shift toward greater project leader influence over clinical decisions.
When scale values for the seven locus of influence constructs are correlated with senior manager assessments of project schedule and overall performance (controlling for priority) a deceptively simple picture emerges. Overall performance is higher when functional managers have greater influence over go/no go (r = .25, p < .05) and budget decisions (r = .27, p < .05), and schedule performance is better when project leaders have greater influence over clinical decisions (r = -.26, p < .O5)(A negative correlation indicates that greater influence by the project leader is associated with higher performance). These relationships become more complex and contingent when projects are split by phase and by leadership structure.
When split into early and late phase projects, the correlations between the locus of go/no go decision influence and performance strengthens for late phase projects and disappears for early stage projects ( Table 9 ). The correlations among locus of influence in budget decisions, reward decisions and overall performance undergo a similar change. Stronger functional control is associated with higher performance only for late stage projects.
A further finding is that functional control over personnel decisions is associated with better schedule performance for early stage projects. When split by leadership structure, the correlation coefficients are not particularly interesting. Only the correlations between the locus of influence over preclinical decisions and performance are significant (schedule r = .39, p < .05; overall r = .36, p < .05). A more interesting comparison is between the means for the two leadership structures. There are significant differences between these two groups for five of the seven decision influence scales and for both schedule and overall performance (Table 10) .
There is clearly a relationship between leadership structure and performance that is not revealed by simple correlation analysis. A multivariate technique is employed The Z-statistic indicates that the correlations for early and late phase projects among technical knowledge and schedule performance (Z = 2.07) and technical knowledge and overall (Z = 2.71) performance are statistically significantly different from each other. It appears that team leader technical knowledge is associated with higher performance only in late phase projects, and, possibly, negatively for early stage projects. Separating teams into those operating in single versus dual leader systems reveals that in dual leader systems a project leader's human relations/political skills and team members' perceptions of the leader's willingness and ability to provide feedback are strongly related to schedule and overall performance ( Table 11 ). For single leader teams the corresponding correlations are negative, and while three of the four are statistically significant at only the p < . 10 level there does appear to be a difference in the characteristics team leaders operating in dual versus single leader systems require to be successful. A t-test of the four project leader characteristics means between the single and dual leader structures shows a significant difference only for technical knowledge of the team leader (4.7 versus 5.4, p < .01).
Team Functioning and Project Performance
Team members' perceptions of organizational milieu are noteworthy because team performance is correlated with both team functioning scales (Table 12) , and because the three items that make up the teamoriented arrangements scale have extremely low values ( Table 7) . Team members across firms in the sample do not feel that teams have autonomy to carry out their mission, that their individual rewards are linked to their performance as team members, or that there are clear criteria for assessing team performance. While it is not possible to make unequivocal claims without data from teams in other industries with which to compare, interviews with team members indicate that attempts Project &
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to empower teams in pharmaceutical firms have not been completely successful, When divided into early and late phase projects the correlations between both team functioning scales and performance strengthen for late stage projects and dramatically weaken for early stage projects. Team functioning is correlated with performance only for late phase projects.
Locus of Decision Influence
Path Analysis
Path analysis was performed to put the results of the correlation analyses into a more succinct multivariate form. The initial model that guided this analysis is shown in Figure 2 . Embedded within the model are a series of hypotheses. The first one is that the locus of decision making has an effect on project performance. The second is that team functioning has an effect on project performance. The third hypothesis embedded within the model is that perceptions of a project leader's characteristics affects project performance directly as well as indirectly through the project leader's affect on the locus of decision making influence and through his or her effect on team functioning. Finally, priority is expected to have an effect upon the characteristics of the project leader and upon the performance of the project.
Team Oriented
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Hierarchical regression was employed to estimate the model parameters. Project priority as assessed by senior managers, phase of the project, and whether teams operated within a single or dual leader system are entered into the regression model first. This is done to test the incremental explanatory power of the other variables added to the model. The selection of which variables to include was guided partly by theory and past research and partly by trial and error. The results for one of the path analytic models tested are shown in Figure 3 .
The conclusions that can be drawn from this model are: This relationship is more complex, however, because the direct negative effect is counteracted by indirect and interaction effects. Perceptions of project leader technical knowledge are positively correlated with a more teamoriented milieu and with greater project leader influence over clinical decisions. There is also an interaction effect between technical knowledge of the project leader and phase. Late stage projects headed by project leaders who are perceived as more technically knowledgeable perform better. Alternatively, early stage projects that are led by managers perceived as more technically knowledgeable perform less well. It is possible that during the early phase of development when technical uncertainty is greater, the best decisions are made by those who have greater expertise in particular technological fields, and 6. Project leaders for late phase projects are likely to have greater influence over go/no go decisions, even though higher performance is correlated with functional influence over these decisions.
It is possible that the project leader and team develop ownership of the project over time, and may lose objectivity in assessing the probability of success and the viability of the drug in the marketplace.
DISCUSSION
The results presented above support the hypothesis that the uncertainty of drug development decreases as compounds move through preclinical and clinical testing. Successful organization structures and project coordination systems need to accommodate these changes. The results demonstrate that the dual leadership structure is superior to the single leader system, at least for this sample of projects. This supports Clark and Fujimoto's finding that heavyweight product managers help move projects through development quickly. The project heads are more senior and have more clout in firms with a dual leadership system. But the story is more complex. The relationship of the project leader's technical knowledge with performance indicates that some technical decisions are best made by the functional side of the organization. The argument can be made that at moments when the task entails significant technical uncertainty, functional expertise should influence decisions, and when the technical uncertqinty of the task is lower and efficiency is more important, the project leader should have more influence. Finally, the results highlight the difficulties inherent in moving to a more team-based approach. The organizational supports for teams are not well developed at this point.
Coordinating the activities of interdependent actors is an essential precursor to coherent action and effective task accomplishment in organizations. For a complex task such as drug development, people with expertise in a broad range of scientific, technological, and business disciplines are brought together to work on a multidisciplinary team to produce a series of decisions and actions that result in some outcome for a project.
As part of accomplishing this an important question for managers in the pharmaceutical industry is: How can a development organization be structured so as to have effective project coordination? This question is very broad, but there are a number of smaller and more focused questions that can be asked in designing an organization. Where does monitoring occur in the organization? What information is monitored? Who attends to this information? Who has the knowledge and interest to influence various decisions and decision makers? Who has the authority to make decisions in response to the information? Who is responsible for resultant outcomes? How are rewards allocated?
The following guidelines may be helpful to managers when making decisions regarding the above questions:
